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Available online 11 November 2016Background:With the expected growth and aging of the population of primary central nervous system tumours
(PCNST) survivors, attention to the radiation-induced late brain injury is fundamental. Late focal hemosiderin de-
position (FHD) lesions, namely microbleeds and cavernomas, are among the presumable late cerebrovascular
complications associated with radiotherapy for PCNST.
Objective: To explore association between PCNST radiotherapy and the occurrence FHD lesions and to address the
correlation between the topographic location of thesemicrovascular lesionswith the focal radiotherapy location.
Methods: Retrospective cohort study of 190 paediatric patients being followed for PCNST in a single referral on-
cological centre. The frequency of FHD lesions was compared between paediatric PCNST treated (n = 132) and
not treated (n= 58) with brain radiation. Microbleed Anatomical Rating Scale (MARS) was used for systematic
identification of these cerebrovascular lesions and to address the consistency between the topographic location
of each lesion and the location of the focal radiotherapy area. Univariate analysis to address the role of variables
such as tumour histology, location, gender and age of children at the beginning of radiotherapy, duration of fol-
low-up and chemotherapy was performed.
Results: FHD lesions (microbleeds and cavernomas) occurred exclusively and in a high percentage (41.6%) in
PCNST survivors treated with brain radiation. Younger age at the diagnosis (p = 0.031), duration of follow-up
(p=0.010) and embryonal histology (p=0.003) positively correlatedwith the occurrence FHD lesions. FHD le-
sions were topographically concordant with the brain focal irradiation area in 3/19 (15.8%) patients from the
focal RT subgroup and in 22/111 (19.8%) patients from the WBRT plus focal RT subgroup.
Conclusion:Our study,which is one of the largest to date on the topic, shows that FHD lesions are a common com-
plication after radiotherapy for childhood PCNST. The young brain is probably more susceptible to radiation-in-
duced late cerebrovascular injury. Diffuse small vessel disease and ceiling effect may account for the low
topographic concordance we found. The clinical implications of FHD lesions in this specific population are yet
to be clarified.






The overall survival of childhood primary central nervous system tu-
mours (PCNST) increased in the last decades [1]. As this population
ages, new challenges will rise to health care providers, with emphasis
on the diagnosis and management of late sequelae from treatment,dical Sciences and Medicine,
ortugal.including radiation-induced cerebrovascular damage [2]. Microbleeds
and cavernomas can be grouped as focal hemosiderin deposition
(FHD) [3] and are imaging markers of radiation-induced small vessel
disease (SVD) [4]. Both are best detected using either susceptibility-
weighted imaging (SWI) or T2*-weighted gradient-recalled echo
(GRE) sequences [3,5]. Microbleeds are also associated with cognitive
impairment in the general population [5–7] and very recently, were
found to be associated with neurocognitive dysfunction in PCNST survi-
vors after radiotherapy (RT) [8]. The underling mechanism between RT
and the occurrence of FHD is not yet fully understood. The purpose of
414 J. Passos et al. / Journal of the Neurological Sciences 372 (2017) 413–416the present study was to depict, quantify and locate FHD lesions, and to




All paediatric patients with central nervous system tumours follow-
ed in our neuro-oncology unit from January 1973 to August 2015 were
reviewed. Patients with at least 1 GRE sequence acquisition in our
hospital's medical image database were included (this MRI sequence
was introduced in our imaging protocol in 2006).
2.2. Data collection
All patients were regularly followed in a dedicated outpatient con-
sultation, with at least one visit each year and at least one brain MRI
each year. Data on demographic information (age, age at brain tumour
diagnosis, gender, race), tumour characteristics (location, pathology),
and treatment (resection, RT dose, RT volume, chemotherapy) were re-
trieved from the patients' electronic andmanual clinical charts. Only the
first GRE sequence acquisition was included in the present study.
2.3. Acquisition and imaging data extraction
EachMRI exam, including axial FSE T1 (TR/TE 543/12ms, 280 × 168,
5/1 mm); FSE DP/T2; (TR/TE 3312/11/100 ms, 332 × 216, 5/1 mm);
FLAIR (TR/TI/TE 11000/2800/140; 280 × 168, 5/1 mm); GRE T2* (TR/
TE 760/23 ms; 280 × 168, 5/1 mm), 3D T1 after gadolinium (TR/TE
8.3/3.8 s, 256 × 256, 1/0mm), was independently reviewed by a neuro-
radiologist (AB) and, at least, one neurologist (SN; AA; JP). Concordance
ratewas 78.2% (104/133). Discordant readingswere reviewed, and con-
sensuswas achieved after discussionwith the attending senior neurora-
diologist (AB, with 15 years of experience). We used the Microbleed
Anatomical Rating Scale (MARS) for topographic and quantitative char-
acterization of FHD lesions [9]. RT volume was determined using 3D RT
fields or inferred using pre-treatment images or clinical data validated
by a radiation oncologist blinded for MARS' results. Microbleed wasFig. 1. Illustrative focal hemosiderin deposition lesions on axial brainmagnetic resonance. Left o
left centrum semiovale (G–I), type III right parietal cavernoma and onemicrobleed on the right
image.defined by the presence of a small rounded or ovoid well-defined
hypointense lesion on GRE sequence, surrounded by brain parenchyma
in at least half of the lesion (to avoid exclusion of cortical microbleeds),
indistinct on T1 and T2-weighted MRI images (Fig. 1 – Illustrative im-
ages). A cut-off value of 2 mm was used and the potential mimickers
(calcium deposits, vessel flow void and traumatic brain injury)were ex-
cluded by image or history [6]. All lesionswithin a 0.5 cmmargin around
the surgical resection site were excluded. We considered cavernoma all
GRE lesions well seen on T1 or T2 that could be categorized using
Zabramski cavernomas classification10: [Type I – hyperintense core on
T1 and hypointense rim on T2 (subacute haemorrhage)]; [Type II – re-
ticular core on both T1 and T2 and hypointense rim on T2 (loculated
areas of haemorrhage and thrombosis of varying age, surrounded by
gliotic, hemosiderin stained brain)]; [Type III – iso or hypointense on
T1 and hypointense rim on T2 (chronic resolved haemorrhage)] (Fig. 1
– Illustrative images). Both microbleeds and cavernomas were grouped
as FHD lesions for the present analysis. The RT treatment was catego-
rized as eitherwhole brain radiotherapy (WBRT), focal or a combination
of the two (in the craniospinal treated patients, only brain RT was con-
sidered, so they all fell in the WBRT category).
2.4. Statistics
All variableswere analysed using descriptive statisticmeasures. Pro-
portions' comparison using chi-square tests and Student t-tests were
used to evaluate the association between: FHD and RT; FHD and RT
type; FHD location and RT field. Confidence intervals were calculated
by exact methods and a significance level of 0.05 was considered. The
analysis was performed using SPSS software for Windows. The retro-
spective chart review and the study were approved by the Institutional
Review Board.
3. Results
Of the 579 paediatric patients with PCNST of our institutional data-
base, 190 had at least one brain GRE imaging during the follow-up peri-
od. One-hundred and nine (57.3%) were male. The mean age at the
diagnosis of PCNST was 8.2 years (range 0–16 years) and 7.5 years
(range 0–15 years) for the RT treated (n = 132) and non-RT treatedccipitalmicrobleed (A–C), coexistentmultiplemicrobleeds (D–F), type 1 cavernomaon the
frontal lobe (J–L). T1=T1weighted image ; T2=T1weighted image; T2*=T2*weighted
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133.0 months, with 15,005.0 patient-years of follow-up. Embryonal
(42.4%), ependymal (17.4%) and low grade astrocytic (15.9%) tumours
accounted for the majority of PCNST in the RT positive group, whereas
low grade astrocytic (43.1%), embryonal (13.8%) and neuronal/mixed
neuronal-glial (8.6%) tumours were the commonest PCNST in non-irra-
diated patients (Table 1). The differences in the clinical management
between the RT positive and RTnegative group expanded to other treat-
ment modalities (chemotherapy, surgery or combination of both). The
median andmean age at the end of RTwas 8 and 8.3 years respectively.
The majority of patients received a combination of WBRT plus focal RT
(50.8%) or focal RT (46.2%). FHD lesions occurred in 55/41.6% patients,
all in the RT positive group. A total of 133 FHD lesions were identified:
119 microbleeds and 14 cavernomas (3 type I, 1 type II and 10 type
III). Topographic concordance analysis was performed in 53 patients
(after exclusion of 2WBRT patients with FHD lesions). The correspond-
ing 129 lesions were distributed between two subgroups: focal RT, 12/
61 (19.7%), with 19 lesions (mean 1.5, median 1.5 lesions/patient);
WBRT plus focal RT, 41/67 (61.2%),with 111 FHD lesions (mean2.6,me-
dian 2 lesions/patient). The FHD lesions were topographically concor-
dant with the brain focal irradiation area in 3/19 (15.8%) patients from
the focal RT subgroup and in 22/111 (19.8%) patients from the WBRT
plus focal RT subgroup. Younger age at the time of diagnosis (p =
0.031), tumour histology (p = 0.003), longer follow-up (p = 0.010),
WBRT treatment (p b 0.001), and longer time interval betweenRT treat-
ment and GRE imaging (p=0.0007)were associatedwith an increased
risk of FHD lesions. Gender (p=0.588) and age at RT (p=0.191) were
not associated with FHD lesions.Table 1



















SX + RT + CT
Age of RT (years)




Only WBRT (n = 4)1
WBRT combined with boost (n = 67)
Only focal (n = 61)2
Boost (focal combined with WBRT) n = 67
Medulla (n = 57)
Follow-up (years)
GRE T2* lesions MB
CV
MB + CV
Time RT ↔ 1st T2* (years)
Time SX ↔ 1st T2* (years)
Time CT ↔ 1st T2* (years)
Age at 1st T2* (years)
Sx: Surgery; CT: Chemotherapy; RT: Radiotherapy; WBRT:; MB:; CV: T2*: weighted gradient-r4. Discussion
In this large cohort of childhood PCNST, we have shown that FHD le-
sions, namely microbleeds and cavernomas, occurred exclusively in
childhood PCNST patients treated with RT. In our analysis, we used
the current international definitions for microbleeds and cavernomas
[6,10] and grouped them under a broader designation (FHD), which
covers a spectrum of imaging changes that are closely related [4]. FHD
lesions occurred in a high percentage (41.6%) of PCNST patients treated
with RT. We previously reported a smaller FHD prevalence (33%)
among survivors of childhood PCNST treated with RT [4]. We believe
that the systematic application of MARS improved the diagnostic sensi-
tivity. Younger age at the diagnosis, embryonal histology, and the dura-
tion of follow-up were positively correlated with the diagnosis of
microbleeds and cavernomas. Gender and age at RT treatment did not
contribute to the occurrence of FHD. A thorough cavernoma characteri-
zation was beyond the scope of this study, nevertheless, the wide dis-
persion of lesion types (from I to III) suggests an ongoing dynamic
brain SVD.
Both GRE acquisition with 5 mm slice thickness and the exclusion of
smaller lesions (b2 mm) probably contributed for an underestimation
of FHD, and we suspect that FHD prevalence may be higher. The topo-
graphic correlation between FHD and RT using MARS was low in both
subgroups: 15.8% in focal RT and 19.8% inWBRT plus focal. More lesions
per patient were found in the WBRT plus focal subgroup. We
hypothesise that a ceiling effect accounts for the low topographic con-
cordance between RT volume and FHD distribution in WBRT plus focal
RT subgroup. Both subgroups were equally affected by the MARSf childhood PCNST.
RT positive group (n = 132) RT negative group (n = 58)
n % n %
51 38.6 30 51.7
81 61.4 28 48.3
8.2* (0–16) 7.5* (0–15)
56 42.4 8 13.8
23 17.4 4 6.9
21 15.9 25 43.1
19 14.4 3 5.2
1 0.8 5 8.6
1 0.8 4 6.9
11 8.3 9 15.5
– – 17 29,3
– – 3 5,2
– – 15 25,9
– – 23 39,7
8 6,1 – –
3 2,3 – –
36 27,3 – –
85 64,4 – –
8.3 (1–17) NA NA
67 50.8 NA NA
61 46.2 NA NA
4 3.0 NA NA
NA NA
38.0/40.0 24.0/50.0 NA NA
34.7/36.0 17.2/40.0 NA NA
53.2/54.0 24.0/60.0 NA NA
19.8/18.0 14.0/54.0 NA NA
34.1/36.0 23.0/40.0 NA NA
11.4/11.0* (0−32) 4.7/2.3* (0–32)
42 31.8% – –
2 1.5% – –
11 8.3% – –
8.1 (0–24) NA NA
8.1 (0–24) 5.5 (0–32)
8.1 (0–24) 5.3 (0–14)
16.9 (2–37) 11.6 (2–39)
ecalled echo.
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volume distribution that is key in focal RT characterization. RT fields'
pathway may equally affect close anatomic structures that would be
classified as non-related using MARS (cerebellum and occipital lobe,
or temporal lobe and hypothalamus e.g.). In our opinion, the increased
number of lesions in theWBRT subgroup is explained by the larger vol-
ume of brain parenchyma exposed to higher doses of radiation.
Ionizing radiation damage encompasses direct and indirect injury.
[11] SVD after RT is most probably a dynamic process involvingmecha-
nisms such as increased expression of vascular endothelial growth fac-
tor (VEGF), blood brain barrier damage, oxidative stress and
inflammation [11].
There is scarce literature addressing the clinical impact of FHD in this
specific population. Cognitive dysfunction was very recently shown to
be more common in survivors of paediatric brain tumour after cranial
radiation therapy [8,12]. The risk of all type of strokes and of symptom-
atic intracerebral haemorrhage after thrombolysis for acute ischemic
stroke is increased in the patients with microbleeds [13,14]. Direct ex-
trapolations of this risk from the general population may not be appro-
priate. The underlying pathophysiology of deep brain or cortical
microbleeds from hypertensive vasculopathy or amyloid vasculopathy
respectively is very different from the radiation-induced SVD. In addi-
tion, patients with radiation-induced FHD are younger and have less
comorbidities.
In conclusion, our study, which is one of the largest to date on the
topic, showed that FHD lesions are common after RT for PCNST and
occur diffusely in the brain. The high frequency of FHD lesionsmerits at-
tention as a possible model for future preventive interventions. As
PCNST survivors grow older, further investigation is warranted. Dose-
volume characterization may clarify if there is any dose distribution de-
pendence to these events and, in the future, help physicians tailor RT
treatment. Longer follow-up studies will probably demonstrate the
full scope of cerebrovascular damage in this population, and will cer-
tainly have an impact on the risk-benefit judgment prior to RT
treatment.
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